Phase 1 to Evaluate the Safety and Pharmacokinetic Characteristics of Fixed-dose Combination of YYC506

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04874129

Enrollment

Registered

2021-05-05

Start date

2021-01-07

Completion date

2021-07-31

Last updated

2021-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemias

Brief summary

To evaluate the safety and pharmacokinetics characteristics between YYC506 and concomitant administration of YYC506-T and YYC506-A

Detailed description

Phase 1 to evaluate the safety and pharmacokinetics characteristics between YYC506 and concomitant administration of YYC506-T and YYC506-A. Which is designed as ramdomized, oral, single dose, two-way crossover.

Interventions

DRUGYYC506-T and YYC506-A (phase 1)

Comparator

DRUGYYC506 (phase 1)

Test

DRUGYYC506-T and YYC506-A (phase 2)

Comparator

DRUGYYC506 (phase 2)

Test

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

ramdomized, open-label, single-dose, two-way crossover study

Eligibility

Sex/Gender

MALE

Age

19 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Over 19 ages healthy men * Over 50.0kg, 18.0kg/m2 ≤ BMI ≤ 30.0kg/m2 * Men who don't have congenital disease and other cronic disease need to be cared. etc.

Exclusion criteria

* Men who have congenital liver disease (AST, ALT, CK ≥ 2X ULN) * Men who have drunken or eatten something including caffeine within 24 hours before. etc.

Design outcomes

Primary

Measure	Time frame	Description
Pharmacokinetic parameters: Cmax	Until 48 hours	Cmax
Pharmacokinetic parameters: AUC	Until 48 hours	YYC506-T, YYC506-A, YYC506 AUC

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026